Recombinant toxin-coregulated pilus A (TcpA) as a candidate subunit cholera vaccine
,
Abstract
Background and Objectives: The toxin co-regulated pilus A (TcpA) has been described as a criti- cal pathogenicity factor of Vibrio cholerae. TcpA is a candidate for making subunit vaccine against chol- era. The aim of this study was to produce a candidate vaccine by expressing recombinant TcpA in E. coli.
Materials and Methods: In this study, the toxin co-regulated pilus A gene from EL-Tor, V. cholerae subspecies, was am- plified by PCR and sub-cloned into prokaryotic expression vector pGEX4T1. E. coli BL21 (DE3) was transformed with pGEX4T1- TcpA and gene expression was induced by IPTG and purified by GST resin. The integrity of the product was confirmed by Western blot analysis using a standard rabbit anti-V. cholerae antibody. Sera reactivity of infected individuals was further analyzed against the recombinant TcpA protein.
Results: The concentration of purified recombinant protein was calculated to be 8 mg/L of initial culture. The in- tegrity of product was confirmed by Western blot analysis using a standard rabbit anti V. cholerae antibody. Sera re- activity of infected individual was further analyzed against the recombinant TcpA protein. The obtained data in- dicated that recombinant TcpA protein from V. cholerae was recognized by patient serum and animal sera.
Conclusion: These results show that the recombinant TcpA is antigenic and could be used in a carrier host as an oral vaccine against cholera.
Herrington DA, Hall RH, Losonsky G, Mekalanos JJ, Taylor RK, Levine MM. Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med 1988; 168: 1487-1492.
Wu JY, Wade WF, Taylor RK. Evaluation of cholera vaccines formulated with toxin-coregulated pilin peptide plus polymer adjuvant in mice. Infect Immun 2001; 69:7695-7702.
Levine MM, Kaper JB, Herrington D, Ketley J,Losonsky G,Tacket CO, et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet 1988; 2: 467-470.
Clemens JD, Sack DA, Harris JR, Van Loon F, Chakraborty J, Ahmed F, et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow- up. Lancet 1990; 335: 270-273.
Levine MM, Kaper JB. Live oral vaccines against cholera: an update. Vaccine 1993; 11: 207-212.
Tacket CO, Cohen MB, Wasserman SS, Losonsky G, Livio S,Kotloff K, et al. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. Infect Immun 1999; 67: 6341-6345.
Tacket CO, Losonsky G, Nataro JP, Cryz SJ,Edelman R,Kaper JB, et al. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J Infect Dis 1992; 166: 837-841.
Fournier JM, Villeneuve S. Cholera update and vaccination problems. Med Trop (Mars) 1998; 58: 32-35.
Tacket CO, Kotloff KL, Losonsky G, Nataro JP, Michalski J, Kaper J, B et al. Volunteer studies investigating the safety and efficacy of live oral El Tor Vibrio cholerae O1 vaccine strain CVD 111. Am J Trop Med Hyg 1997; 56: 533-537.
Taylor DN, Tacket CO, Losonsky G, Castro O, Gutierrez J, Meza R, et al. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru. Infect Immun 1997; 65: 3852-3856.
Kimsey HH, Waldor MK. CTXphi immunity: application in the development of cholera vaccines. Proc Natl Acad Sci U S A 1998; 95: 7035-7039.
Abtahi H, Moradkhani A, Pakzad I. Cloning and Expression of the Streptococcus pyogenes Hyaluronidase Gene in E. coli. Aust J Basic & Appl Sci 2012; 6: 95-99.
Molaee N, Abtahi H, Mosayebi G. Expression of Recombinant Streptokinase from Streptococcus Pyogenes and Its Reaction with Infected Human and Murine Sera. Iran J Basic Med Sci. 2013; 16: 985-989.
Kamani M, Abtahi H, Nazari R, Pakzad I. Recombinant Streptodornase Production in Escherichia coli. Aust J Basic & Appl Sci 2011; 5: 2343-2347.
Farjadi V, Abtahi H, Zolfaghari, Safieh Soufian MR, Hasanzadeh L . Expression, Purification and Evaluation of Antigenicity of CagA Antigenic Fragment of Helicobacter pylori. Jundishapur J Microbiol 2013; 6: e7367.
Hasanzadeh L, Ghaznavi-Rad E, Soufian S, Farjadi V, Abtahi H. Expression and Antigenic Evaluation of VacA Antigenic Fragment of Helicobacter Pylori. Iran J Basic Med Sci 2013: 16: 836-839.
Taylor RK, Kirn TJ, Meeks MD, Wade TK, Wade WF. A Vibrio cholerae classical TcpA amino acid sequence induces protective antibody that binds an area hypothesized to be important for toxin-coregulated pilus structure. Infect Immun 2004; 72: 6050-6060.
Rollenhagen JE, Kalsy A, Cerda F, ohn M, Harris JB, Larocque RC, et al. Transcutaneous immunization with toxin-coregulated pilin A induces protective immunity against Vibrio cholerae O1 El Tor challenge in mice. Infect Immun 2006; 74: 5834-5839.
Lipscombe M, Charles IG, Roberts M, Dougan G, Tite J, Fairweather NF. Intranasal immunization using the B subunit of the Escherichia coli heat-labile toxin fused to an epitope of the Bordetella pertussis P.69 antigen. Mol Microbiol 1991; 5: 1385-1392.
Zhang RG, Scott DL, Westbrook ML, Nance S, Spangler BD, Shipley GG, et al. The three-dimensional crystal structure of cholera toxin. J Mol Biol 1995; 251: 563-573.
Manning PA. The tcp gene cluster of Vibrio cholerae.Gene 1997; 192: 63-70.
Taylor RK, Kirn TJ, Bose N, Stonehouse E, Tripathi SA, Kovác P, Wade WF, et al. Progress towards development of a cholera subunit vaccine. Chem Biodivers 2004; 1:1036-1057.
Hall RH, Losonsky G, Silveira AP, Taylor RK, Mekalanos JJ, Witham ND, et al. Immunogenicity of Vibrio cholerae O1 toxin-coregulated pili in experimental and clinical cholera. Infect Immun 1991;59: 2508-2512.
Iredell JR, Manning PA. Biotype-specific tcpA genes in Vibrio cholerae. FEMS Microbiol Lett 1994; 121: 47-54.
Jonson G, Holmgren J, Svennerholm AM. Epitope differences in toxin-coregulated pili produced by classical and El Tor Vibrio cholerae O1. Microb Pathog 1991; 11: 179-188.
Craig L, Taylor RK, Pique ME, Adair BD, Arvai AS, Singh M, et al. Type IV pilin structure and assembly: X-ray and EM analyses of Vibrio cholerae toxin- coregulated pilus and Pseudomonas aeruginosa PAK pilin. Mol Cell 2003; 11: 1139-1150.
Sun DLM, Peek JA, Taylor RK. Domains within the Vibrio cholerae toxin coregulated pilin subunit that mediate bacterial colonization. Gene 1997; 192: 79-85.
Gelber RH, Mehra V, Bloom B, Murray LP, Siu P, Tsang M, et al. Vaccination with pure Mycobacterium lepare proteins inhibits M. leprae multiplication in mouse footpads. Infect Immun 1994; 62: 4250-4255.
Khusmith S1, Charoenvit Y, Kumar S, Sedegah M, Beaudoin RL, Hoffman SL. Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein. Science 1991; 252: 715-718.
| Files | ||
| Issue | Vol 6 No 2 (2014) | |
| Section | Articles | |
| Keywords | ||
| Escherichia coli Recombinant Toxin co-regulated pilus Vaccine Vibrio cholerae | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
